{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:30:44Z","timestamp":1789500644893,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"crossref","award":["16K10494"],"award-info":[{"award-number":["16K10494"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Interleukin-17A (IL-17A) is pro-inflammatory cytokine and acts as profibrotic factor in the fibrosis of various organs. Fibrosis tumor-like peritoneal dissemination of gastric cancer interferes with drug delivery and immune cell infiltration because of its high internal pressure. In this study, we examined the relationship between IL-17A and tissue fibrosis in peritoneal dissemination and elucidated the mechanism of fibrosis induced by IL-17A using human peritoneal mesothelial cells (HPMCs) and a mouse xenograft model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seventy gastric cancer patients with peritoneal dissemination were evaluated. The correlation between IL-17A and fibrosis was examined by immunofluorescence and immunohistochemistry. A fibrosis tumor model was developed based on subcutaneous transplantation of co-cultured cells (HPMCs and human gastric cancer cell line MKN-45) into the dorsal side of nude mice. Mice were subsequently treated with or without IL-17A. We also examined the effect of IL-17A on HPMCs in vitro.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was a significant correlation between IL-17A expression, the number of mast cell tryptase (MCT)-positive cells, and the degree of fibrosis (<jats:italic>r<\/jats:italic>\u2009=\u20090.417, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). In the mouse model, IL-17A enhanced tumor progression and fibrosis. HPMCs treated with IL-17A revealed changes to a spindle-like morphology, decreased E-cadherin expression, and increased \u03b1-SMA expression through STAT3 phosphorylation. Moreover, HPMCs treated with IL-17A showed increased migration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IL-17A derived from mast cells contributes to tumor fibrosis in peritoneal dissemination of gastric cancer. Inhibiting degranulation of mast cells might be a promising treatment strategy to control organ fibrosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10120-020-01092-2","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T09:11:43Z","timestamp":1591089103000},"page":"31-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Interleukin-17A derived from mast cells contributes to fibrosis in gastric cancer with peritoneal dissemination"],"prefix":"10.1007","volume":"24","author":[{"given":"Katsuya","family":"Gunjigake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itasu","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5567-7383","authenticated-orcid":false,"given":"Sachio","family":"Fushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"1092_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/1097-0142(19890215)63:4<613::AID-CNCR2820630402>3.0.CO;2-0","volume":"63","author":"H Yamazaki","year":"1989","unstructured":"Yamazaki H, Oshima A, Murakami R, Endoh S, Ubukata T. Long-term follow-up study of patients with gastric cancer detected by mass screening. Cancer. 1989;63:613\u20137.","journal-title":"Cancer"},{"key":"1092_CR2","first-page":"874","volume":"49","author":"CY Chen","year":"2002","unstructured":"Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 2002;49:874\u20137.","journal-title":"Hepatogastroenterology"},{"key":"1092_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10120-006-0370-y","volume":"9","author":"K Maruyama","year":"2006","unstructured":"Japanese Gastric Cancer Association Registration Committee, Maruyama K, Kaminishi M, Hayashi K, Isobe Y, Honda I, et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006;9:51\u201366.","journal-title":"Gastric Cancer"},{"key":"1092_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(09)60617-6","volume":"374","author":"HH Hartgrink","year":"2009","unstructured":"Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477\u201390.","journal-title":"Lancet"},{"key":"1092_CR5","first-page":"1305","volume":"19","author":"S Fushida","year":"2008","unstructured":"Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008;19:1305\u201310.","journal-title":"Oncol Rep"},{"key":"1092_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","volume":"71","author":"S Fushida","year":"2013","unstructured":"Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71:1265\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1092_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15252\/emmm.201505948","volume":"8","author":"RM Carr","year":"2016","unstructured":"Carr RM, Fernandez-Zapico ME. Pancreatic cancer microenvironment, to target or not to target? EMBO Mol Med. 2016;8:80\u20132.","journal-title":"EMBO Mol Med"},{"key":"1092_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/path.2667","volume":"220","author":"OJ de Boer","year":"2010","unstructured":"de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, van Maldegem F, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220:499\u2013508.","journal-title":"J Pathol"},{"key":"1092_CR9","doi-asserted-by":"publisher","first-page":"e106834","DOI":"10.1371\/journal.pone.0106834","volume":"9","author":"X Liu","year":"2014","unstructured":"Liu X, Jin H, Zhang G, Lin X, Chen C, Sun J, et al. Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients. PLoS ONE. 2014;9:e106834.","journal-title":"PLoS ONE"},{"key":"1092_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10238-018-0493-6","volume":"18","author":"V Longo","year":"2018","unstructured":"Longo V, Tamma R, Brunetti O, Pisconti S, Argentiero A, Silvestris N, et al. Mast cells and angiogenesis on pancreatic ductal adenocarcinoma. Clin Exp Med. 2018;18:319\u201323.","journal-title":"Clin Exp Med"},{"key":"1092_CR11","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00262-013-1460-4","volume":"62","author":"B Wang","year":"2013","unstructured":"Wang B, Li L, Liao Y, Li J, Yu X, Zhang Y, et al. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2013;62:1575\u201385.","journal-title":"Cancer Immunol Immunother"},{"key":"1092_CR12","doi-asserted-by":"publisher","first-page":"e3220","DOI":"10.1097\/MD.0000000000003220","volume":"95","author":"JF Tu","year":"2016","unstructured":"Tu JF, Pan HY, Ying XH, Lou J, Ji JS, Zou H. Mast cells comprise the major of interleukin 17-producing cells and predict a poor prognosis in hepatocellular carcinoma. Medicine (Baltimore). 2016;95:e3220.","journal-title":"Medicine (Baltimore)"},{"key":"1092_CR13","volume":"2014","author":"B Yang","year":"2014","unstructured":"Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D. The role of interleukin 17 in tumor proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014;2014:623759.","journal-title":"Mediators Inflamm."},{"key":"1092_CR14","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1007\/s10620-018-5234-x","volume":"63","author":"HJ Zhang","year":"2018","unstructured":"Zhang HJ, Zhang YN, Zhou H, Guan L, Li Y, Sun MJ. IL-17A promotes initiation and development of intestinal fibrosis through EMT. Dig Dis Sci. 2018;63:2898\u2013909.","journal-title":"Dig Dis Sci"},{"key":"1092_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4103\/injr.injr_106_17","volume":"13","author":"A Wakhlu","year":"2018","unstructured":"Wakhlu A, Sahoo RR, Parida JR, Rai MK, Miara DP, Agrawal V, et al. Serum interleukin-6, interleukin-17A, and transforming growth factor beta are raised in systemic sclerosis with interstitial lung disease. Indian J Rheumatol. 2018;13:107\u201312.","journal-title":"Indian J Rheumatol"},{"key":"1092_CR16","first-page":"187","volume":"27","author":"ZD Lv","year":"2011","unstructured":"Lv ZD, Na D, Ma XY, Zhao C, Zhao WJ, Xu HM. Human peritoneal mesothelial cell transformation into myofibroblasts in response to TGF-ss1 in vitro. Int J Mol Med. 2011;27:187\u201393.","journal-title":"Int J Mol Med"},{"key":"1092_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3892\/ijo.2012.1490","volume":"41","author":"T Tsukada","year":"2012","unstructured":"Tsukada T, Fushida S, Harada S, Yagi Y, Kinoshita J, Oyama K, et al. The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancer. Int J Oncol. 2012;41:476\u201382.","journal-title":"Int J Oncol"},{"key":"1092_CR18","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.4049\/jimmunol.165.10.5814","volume":"165","author":"J Witwski","year":"2000","unstructured":"Witwski J, Pawlaczyk K, Breborowicz A, Scheruen A, Kuzlan-Pawlaczyk M, Wisniewska J, et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol. 2000;165:5814\u201321.","journal-title":"J Immunol"},{"key":"1092_CR19","first-page":"440","volume":"6","author":"Q Huang","year":"2016","unstructured":"Huang Q, Han J, Fan J, Duan L, Guo M, Lv Z, et al. IL-17 induces EMT via Stat3 in lung adenocarcinoma. Am J Cancer Res. 2016;6:440\u201351.","journal-title":"Am J Cancer Res"},{"key":"1092_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-018-1003-0","volume":"38","author":"S Li","year":"2019","unstructured":"Li S, Cong X, Gao H, Lan X, Li Z, Wang W, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer. J Exp Clin Cancer Res. 2019;38:6.","journal-title":"J Exp Clin Cancer Res"},{"key":"1092_CR21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/onc.2016.291","volume":"36","author":"YX Jiang","year":"2017","unstructured":"Jiang YX, Yang SW, Li PA, Luo X, Li ZY, Hao YX, et al. The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms. Oncogene. 2017;36:1256\u201364.","journal-title":"Oncogene"},{"key":"1092_CR22","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2008-03-147033","volume":"112","author":"B Huang","year":"2008","unstructured":"Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008;112:1269\u201379.","journal-title":"Blood"},{"key":"1092_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.canlet.2014.09.019","volume":"355","author":"M Okazaki","year":"2014","unstructured":"Okazaki M, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, et al. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. Cancer Lett. 2014;355:46\u201353.","journal-title":"Cancer Lett"},{"key":"1092_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"1092_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/089686080602600207","volume":"26","author":"S Yung","year":"2006","unstructured":"Yung S, Li FK, Chan TM. Peritoneal mesothelial cell culture and biology. Perit Dial Int. 2006;26:162\u201373.","journal-title":"Perit Dial Int"},{"key":"1092_CR26","first-page":"795","volume":"8","author":"Y Yonemura","year":"1996","unstructured":"Yonemura Y, Endo Y, Yamaguchi T, Fujimura T, Obata T, et al. Mechanisms of the formation of peritoneal dissemination in gastric cancer. Int J Oncol. 1996;8:795\u2013802.","journal-title":"Int J Oncol"},{"key":"1092_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12885-016-2991-9","volume":"17","author":"M Okazaki","year":"2017","unstructured":"Okazaki M, Fushida S, Harada S, Tsukada T, Kinoshita J, et al. Establishing a xenograft mouse model of peritoneal dissemination of gastric cancer with organ invasion and fibrosis. BMC Cancer. 2017;17:23.","journal-title":"BMC Cancer"},{"key":"1092_CR28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA. The basics of epithelial\u2013mesenchymal transition. J Clin Invest. 2009;119:1420\u20138.","journal-title":"J Clin Invest"},{"key":"1092_CR29","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1084\/jem.20090207","volume":"206","author":"L Wang","year":"2009","unstructured":"Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457\u201364.","journal-title":"J Exp Med"},{"key":"1092_CR30","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1158\/0008-5472.CAN-15-0896","volume":"75","author":"C Loncle","year":"2015","unstructured":"Loncle C, Bonjoch L, Folch-Puy E, Lopez-Millan MB, Lac S, Molejon MI, et al. IL17 functions through the novel REG3beta\u2013JAK2\u2013STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer. Cancer Res. 2015;75:4852\u201362.","journal-title":"Cancer Res"},{"key":"1092_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ccr.2009.01.009","volume":"15","author":"J Bromberg","year":"2009","unstructured":"Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009;15:79\u201380.","journal-title":"Cancer Cell"},{"key":"1092_CR32","doi-asserted-by":"publisher","first-page":"19977","DOI":"10.1073\/pnas.0704620104","volume":"104","author":"E Gounaris","year":"2007","unstructured":"Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA. 2007;104:19977\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1092_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/modpathol.3800474","volume":"19","author":"S Ch\u2019ng","year":"2006","unstructured":"Ch\u2019ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. Mod Pathol. 2006;19:149\u201359.","journal-title":"Mod Pathol"},{"key":"1092_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1471-2407-7-165","volume":"7","author":"RM Amini","year":"2007","unstructured":"Amini RM, Aaltonen K, Nevanlinna H, Carvalho R, Salonen L, Heikkila P, et al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer. 2007;7:165.","journal-title":"BMC Cancer"},{"key":"1092_CR35","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/j.1440-1746.2007.05009.x","volume":"24","author":"M Gulubova","year":"2007","unstructured":"Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 2007;24:1265\u201375.","journal-title":"J Gastroenterol Hepatol"},{"key":"1092_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s004280050037","volume":"436","author":"M Sawatsubashi","year":"2000","unstructured":"Sawatsubashi M, Yamada T, Fukushima N, Mizokami H, Tokunaga O, Shin T. Association of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinoma. Virchows Arch. 2000;436:243\u20138.","journal-title":"Virchows Arch"},{"key":"1092_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000069515","volume":"130","author":"M Aoki","year":"2003","unstructured":"Aoki M, Pawankar R, Niimi Y, Kawana S. Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES. Int Arch Allergy Immunol. 2003;130:216\u201323.","journal-title":"Int Arch Allergy Immunol"},{"key":"1092_CR38","first-page":"19","volume":"1796","author":"S Maltby","year":"2009","unstructured":"Maltby S, Khazaie K, Mcnagny KM. Mast cells in tumor growth: angiogenesis, tissue remodeling and immune-modulation. Biochim Biophys Acta. 2009;1796:19\u201326.","journal-title":"Biochim Biophys Acta"},{"key":"1092_CR39","first-page":"6757","volume":"60","author":"W Zhang","year":"2000","unstructured":"Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. Cancer Res. 2000;60:6757\u201362.","journal-title":"Cancer Res"},{"key":"1092_CR40","first-page":"w13999","volume":"144","author":"T Hugle","year":"2014","unstructured":"Hugle T. Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly. 2014;144:w13999.","journal-title":"Swiss Med Wkly"},{"key":"1092_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10120-017-0726-5","volume":"21","author":"H Saito","year":"2018","unstructured":"Saito H, Fushida S, Harada S, Miyashita T, Oyama K, Yamaguchi T, et al. Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: inhibition of growth and fibrosis by tranilast. Gastric Cancer. 2018;21:55\u201367.","journal-title":"Gastric Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-020-01092-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-020-01092-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-020-01092-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T23:23:57Z","timestamp":1622589837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-020-01092-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1007\/s10120-020-01092-2","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"1 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Kanazawa University Graduate School of Medical Science (No 2789).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights statement"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed. Animals were treated in accordance with the Fundamental Guidelines for the Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions, under the jurisdiction of the Ministry of Education, Culture, Sports, Science, and Technology of Japan. All animal experiments were approved by the Committee on Animal Experimentation of Kanazawa University.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"Informed consent or substitutes for it was obtained from all patients for their inclusion in this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}